Marksans Pharma News and Updates

Name: Latest research reports of Marksans Pharma Ltd. authored by Ventura and published by - Trendlyne research reports.
Item: Marksans Pharma Ltd.
Rating: 5
Author: Ventura

Keep track of all breaking news on Marksans Pharma from all sources in a single place.

Load latest

Marksans Pharma Ltd.

22 Nov 2024

193.86

1.02%

Marksans Pharma gets USFDA nod for allergic rhinitis treatment tablets

Business Standard

Marksans Pharma Ltd on Friday said it has received final approval from the US health regulator for its generic version of Loratadine tablets indicated in the treatment of allergic rhinitis. The approval by the US Food and Drug Administration (USFDA) is for the company's abbreviated new drug application (ANDA) for Loratadine tablets of strength 10 mg, Marksans Pharma said in a regulatory filing. Loratadine tablets are indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for over-the-counter (OTC) use. This product is a generic version of Clartin tablet in the same strength as Bayer Healthcare, the company added. Loratadine is an antihistamine that treats symptoms such as itching, runny nose, watery eyes, and sneezing from "hay fever" and other allergies, it added.

Marksans Pharma Ltd. is trading above its 100 day SMA of 187.7

Marksans Pharma shares climb after USFDA's nod for allergic rhinitis drug

Business Standard | 22 Nov 2024 1 more

Marksans Pharma Ltd.

12 Nov 2024

193.86

1.02%

to see Rapid results content

Marksans Pharma Ltd.

21 Aug 2024

193.86

1.02%

Here's why Marksans Pharma stocks hit 52-week high on August 21; Know more

Business Standard

The surge in the stock price came after the company announced that its wholly owned subsidiary (WOS) Relonchem Limited has secured Marketing Authorisation from UKMHRA for three products.

Marksans Pharma has lost -37.92% in the last 1 Year

Marksans Pharma Ltd.

20 Aug 2024

193.86

1.02%

Marksans Pharma hits 52-week high after USFDA issues EIR for Goa facility

Business Standard

Shares of Marksans Pharma soared up to 1.98 per cent at Rs 220.14 per share on the BSE in Tuesday's intraday trade

Number of FII/FPI investors decreased from 159 to 146 in Sep 2025 qtr

Marksans Pharma Ltd.

14 Aug 2024, 02:10PM

193.86

1.02%

Marksans Pharma stock zooms 16% to hit record high on strong Q1 results

Business Standard

The US & North America Formulation biz reported growth of 29.8% YoY in Q1FY25, on account of incremental revenue from new product launches, and increase in the share of existing customers.